2026 Global: Chest Cancer Molecular Diagnostics Market -Competitive Review (2032) report
Description
The 2026 Global: Chest Cancer Molecular Diagnostics Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for chest cancer molecular diagnostics market by geography and historical trend. The scope of the report extends to sizing of the chest cancer molecular diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The chest cancer molecular diagnostics market, often encompassing breast and lung cancer applications, features ten major companies driving innovation through next-generation sequencing (NGS), liquid biopsies, and companion diagnostics. Leading players include Roche (F. Hoffmann-La Roche Ltd), which dominates with over 30 oncology solutions, including Foundation Medicine's comprehensive genomic profiling for biomarkers like HER2, EGFR, and PD-L1, enabling precise treatments across tissue and liquid biopsies. Thermo Fisher Scientific Inc. excels with Ion Torrent NGS platforms and Oncomine assays for breast and lung cancers, bundling reagents with informatics for high-throughput biomarker detection. Illumina Inc. provides TruSight Oncology kits for rapid CGP, screening hundreds of biomarkers in tumor samples within days, supporting personalized strategies. QIAGEN N.V. offers therascreen kits targeting PIK3CA in breast cancer and KRAS in lung, facilitating targeted therapies via PCR-based assays. Abbott Laboratories contributes automated molecular platforms for estrogen receptor and HER2 testing, integral to routine breast cancer profiling.
Danaher Corporation, through subsidiaries like Cepheid and Beckman Coulter, advances PCR and NGS for oncology, with companion diagnostics like CAPP Dx for KRAS and BRAF mutations in lung and colorectal extensions. Guardant Health specializes in liquid biopsies via Guardant360 CDx, detecting ctDNA for minimal residual disease in advanced breast and lung cancers, aiding therapy selection without invasive procedures. Agilent Technologies delivers in-situ hybridization and mass spectrometry for HER2 and ALK, enhanced by AI analytics for precise pathology in chest tumors. Myriad Genetics leads with BRACAnalysis CDx and myChoice for BRCA mutations in breast cancer, predicting outcomes and guiding PARP inhibitors. bioMérieux and Bio-Rad Laboratories support with multiplex PCR and immunoassays for early detection, though smaller in scale, contributing to biomarker panels amid market growth to USD 6.58 billion by 2030.
These firms pursue vertical integration, partnerships like Roche-Janssen for MRD assays, and AI enhancements, capturing breast cancer's 18% revenue share via established markers while lung leads CAGR at 12.83%. Consolidation, such as Roche's Foundation Medicine acquisition, bolsters leadership, with disruptors like Guardant advancing non-invasive options. Innovations in NGS and CRISPR, as seen in smaller players like Circulogene's TumorClear for NSCLC, pressure majors to innovate, ensuring sustained dominance in precision oncology.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for chest cancer molecular diagnostics market by geography and historical trend. The scope of the report extends to sizing of the chest cancer molecular diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The chest cancer molecular diagnostics market, often encompassing breast and lung cancer applications, features ten major companies driving innovation through next-generation sequencing (NGS), liquid biopsies, and companion diagnostics. Leading players include Roche (F. Hoffmann-La Roche Ltd), which dominates with over 30 oncology solutions, including Foundation Medicine's comprehensive genomic profiling for biomarkers like HER2, EGFR, and PD-L1, enabling precise treatments across tissue and liquid biopsies. Thermo Fisher Scientific Inc. excels with Ion Torrent NGS platforms and Oncomine assays for breast and lung cancers, bundling reagents with informatics for high-throughput biomarker detection. Illumina Inc. provides TruSight Oncology kits for rapid CGP, screening hundreds of biomarkers in tumor samples within days, supporting personalized strategies. QIAGEN N.V. offers therascreen kits targeting PIK3CA in breast cancer and KRAS in lung, facilitating targeted therapies via PCR-based assays. Abbott Laboratories contributes automated molecular platforms for estrogen receptor and HER2 testing, integral to routine breast cancer profiling.
Danaher Corporation, through subsidiaries like Cepheid and Beckman Coulter, advances PCR and NGS for oncology, with companion diagnostics like CAPP Dx for KRAS and BRAF mutations in lung and colorectal extensions. Guardant Health specializes in liquid biopsies via Guardant360 CDx, detecting ctDNA for minimal residual disease in advanced breast and lung cancers, aiding therapy selection without invasive procedures. Agilent Technologies delivers in-situ hybridization and mass spectrometry for HER2 and ALK, enhanced by AI analytics for precise pathology in chest tumors. Myriad Genetics leads with BRACAnalysis CDx and myChoice for BRCA mutations in breast cancer, predicting outcomes and guiding PARP inhibitors. bioMérieux and Bio-Rad Laboratories support with multiplex PCR and immunoassays for early detection, though smaller in scale, contributing to biomarker panels amid market growth to USD 6.58 billion by 2030.
These firms pursue vertical integration, partnerships like Roche-Janssen for MRD assays, and AI enhancements, capturing breast cancer's 18% revenue share via established markers while lung leads CAGR at 12.83%. Consolidation, such as Roche's Foundation Medicine acquisition, bolsters leadership, with disruptors like Guardant advancing non-invasive options. Innovations in NGS and CRISPR, as seen in smaller players like Circulogene's TumorClear for NSCLC, pressure majors to innovate, ensuring sustained dominance in precision oncology.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
